Abstracts Archive - Page 342 of 2425 - ACR Meeting Abstracts

Abstract Number: 2034 • ACR Convergence 2023
Assessment of the Immediate and Short-term Impact of an Information Course on Patients’ Knowledge About Rheumatoid Arthritis: Evaluation Using a Self-prepared and Validated Assessment Questionnaire
Ranjan Gupta¹, Rudra Prosad Goswami², Manshi Yadav¹, Sandhya Saini¹, Anju Mohan¹ and Vanamail Perumal¹, ¹All India Institute of Medical Sciences, New Delhi, India, ²Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients' knowledge, beliefs and perception about their disease which can help them in coping…
Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Ayesha Butt¹, Rolando Garcia Milian¹, George Goshua¹, Sean Gu¹, Eugenia Chock², Valentina Restrepo¹, John Hwa¹, Hyung Chun¹, H Michael Belmont³, Kello Nina⁴, D. Ware Branch⁵, Michelle Petri⁶, Jason Knight⁷, Rohan Willis⁸, Maria Laura Bertolaccini⁹, Doruk Erkan¹⁰, Alfred lee¹, Anish Sharda¹ and Alexander Pine¹¹, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Greenwich, CT, ³NYU School of Medicine, New York, NY, ⁴Northwell Health, Brooklyn, NY, ⁵University of Utah, Salt Lake City, UT, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Texas Medical Branch, Galveston, TX, ⁹King's College London, London, United Kingdom, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹VA Connecticut/Yale School of Medicine, West Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
Abstract Number: 2157 • ACR Convergence 2023
Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis
Maxime Dougados¹, Peter C. Taylor², David Gruben³ and Meriem Kessouri⁴, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc., Paris, France
Background/Purpose: Pain is the most common symptom reported by patients (pts) with rheumatic disorders, such as RA.1 Improvement in pain with antirheumatic drugs is generally…
Abstract Number: 2168 • ACR Convergence 2023
The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis
Gilad Halpert¹, Ori Moskovitch¹, Adi Anaki², Tal Caller¹, Omer Gendelman¹, Abdulla watad¹, Ruty Mehrian-Shai¹, Rachella Popovtzer², Boris Guilbord¹, Ori Segal¹ and Howard AMITAL¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Bar Ilan University, Ramat Gan, Israel
Background/Purpose: The use of biological treatment in patients with rheumatoid arthritis (RA) can induce non-specific immune suppression, which might result in higher rates of infections.…
Abstract Number: 2169 • ACR Convergence 2023
Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial
Joanna Kedra¹, Benjamin Granger², Lina El Houari³, Florence Tubach⁴ and Bruno Fautrel⁵, ¹Sorbonne Université, IPLESP, and Pitié-Salpêtrière Hospital, Paris, France, ²Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ³Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, ⁴Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ⁵Sorbonne Université APHP, Paris, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
Abstract Number: 2164 • ACR Convergence 2023
Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Carlos Sánchez-Piedra¹, Lorena Expósito², PALOMA VELA³, Manuel José Moreno Ramos⁴, Cristina Campos⁵, Cristina Bohorquez⁶, Jerusalem Calvo⁷, Zulema Plaza⁸, Marta Domínguez⁹ and Jose Federico Diaz-Gonzalez¹⁰, ¹Health Technology Assessment Agency (AETS), Instituto de Salud Carlos III, Madrid, Spain, ²Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, ³Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁴Rheumatology Department Hospital Virgen de la Arrixaca, El Palmar Murcia, Spain, ⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ⁷Reina Sofia University Hospital, Córdoba, Spain, ⁸Universidad Autónoma de Madrid, Madrid, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain, ¹⁰Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: Clinical practice guidelines, based on information from clinical trials, provide different recommendations for the use of combination therapies for the treatment of rheumatoid arthritis…
Abstract Number: 2163 • ACR Convergence 2023
Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?
Joy van der Pol¹, Sytske Anne Bergstra², Thomas Huizinga² and CF Allaart², ¹Leiden University Medical Center, Utrecht, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The EULAR recommendations for the treatment of RA state, by expert opinion, that if a treatment target is not achieved with the first csDMARD…
Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Jeffrey Curtis¹, Fenglong Xie¹, Yuji Su², Patrick Stewart³ and Amy S. Mudano¹, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ³Illumination Health, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
Abstract Number: 2162 • ACR Convergence 2023
Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure
René Westhovens¹, Rieke Alten², Lorenzo Dagna³, Arthur Kavanaugh⁴, Kevin Withrop⁵, Jane Barry⁶, Robin Besuyen⁷, Claudio Corallo⁸, Dick de Vries⁹, Nicolas Martin¹⁰, Chris Watson⁶, Mark C. Genovese¹¹, Alberto Spindler¹², Mykola Stanislavchuk¹³, Maria Greenwald¹⁴ and Paul Emery¹⁵, ¹Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ³Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ⁴Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁵Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁶Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ⁷Clinical Development, Galapagos BV, Leiden, Netherlands, ⁸Medical Affairs, Galapagos Biopharma Italy S.R.L., Milan, Italy, ⁹Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, ¹⁰Biostatistics, Galapagos NV, Mechelen, Belgium, ¹¹Clinical Development, Gilead Sciences Inc., Foster City, CA, ¹²Rheumatology Section, Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina, ¹³Rheumatology, National Pirogov Memorial Medical University, Vinnytsia, Ukraine, ¹⁴Rheumatology, Desert Medical Advances, Palm Desert, CA, ¹⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: DARWIN 3 (NCT02065700) is a long-term extension (LTE) study assessing the safety and efficacy of filgotinib (FIL) in patients with rheumatoid arthritis (RA) and…
Abstract Number: 2139 • ACR Convergence 2023
Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort
Namrata Singh¹, Aaron Baraff², K Wysham³, Punyasha Roul⁴, Grant Cannon⁵, Brian Sauer⁶, Geoffrey Thiele⁴, Bryant England⁴, Ted R Mikuls⁷ and Joshua Baker⁸, ¹University of Washington, Bellevue, WA, ²VA Puget Sound Seattle, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: A prior study suggested a higher risk of cancer mortality in patients with rheumatoid arthritis (RA) with higher levels of circulating leptin, an adipocytokine…
Abstract Number: 2140 • ACR Convergence 2023
Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Ted R Mikuls¹, Bryant England², Harlan Sayles², Tate Johnson², Michael Duryee², Carlos Hunter², Joshua Baker³, Gail Kerr⁴, Gary Kunkel⁵, Grant Cannon⁶, Brian Sauer⁷, K Wysham⁸, Amy Joseph⁹, Beth Wallace¹⁰, Geoffrey Thiele² and Jill Poole², ¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸VA Puget Sound/University of Washington, Seattle, WA, ⁹Washington University / St. Louis VA, St. Louis, MO, ¹⁰Ann Arbor VA, Ann Arbor, MI
Background/Purpose: Alarmins are proteins found in the nuclei of epithelial, endothelial, and immune cells that are released following cell damage and act as stress signals.…
Abstract Number: 2151 • ACR Convergence 2023
Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial
Sara Tommasi¹, Richard Woodman¹, Michael Wiese², Michael Shanahan¹ and Arduino Mangoni¹, ¹Flinders University, Adelaide, Australia, ²University of South Australia, Adelaide, Australia
Background/Purpose: Treatment with methotrexate (MTX) has been shown to be associated with lower cardiovascular risk and lower blood pressure (BP) compared with other disease modifying…
Abstract Number: 2148 • ACR Convergence 2023
Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial
Josef S Smolen¹, Peter C. Taylor², Yoshiya Tanaka³, Carlos Cara⁴, Bernard Lauwerys⁵, Ricardo Xavier⁶, Jeffrey R Curtis⁷, Ted R Mikuls⁸ and Michael Weinblatt⁹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴UCB Pharma, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: In patients with RA, high RF titers are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression,…
Abstract Number: 2155 • ACR Convergence 2023
The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies
Peter C. Taylor¹, Arthur Kavanaugh², Peter Nash³, Janet Pope⁴, Georg Pongratz⁵, Bruno Fautrel⁶, Rieke Alten⁷, Ken Hasegawa⁸, Shangbang Rao⁹, Dick de Vries¹⁰, Pieter-Jan Stiers¹¹, Chris Watson¹² and René Westhovens¹³, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴University of Western Ontario, London, ON, Canada, ⁵Faculty of Medicine, Regensburg University, Regensburg, Germany, Regensburg, Germany, ⁶Sorbonne Université APHP, Paris, France, ⁷Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ⁸Global Medical Affairs Research, Gilead Sciences, Inc., Foster City, CA, ⁹Biostatistics, Gilead Sciences, Inc., Foster City, CA, ¹⁰Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, ¹¹Biostatistics, Galapagos NV, Mechelen, Belgium, ¹²Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ¹³Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post hoc analysis…
Abstract Number: 2176 • ACR Convergence 2023
Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis
Robert J. Benschop¹, Jay Tuttle¹, Paul Emery², Christoph Preuss¹, Mark Daniels¹, Veavi Ching-Yun Chan¹, Pia Yachi¹ and Ajay Nirula¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].